Materials & Packaging • Pharmaceutical Research & Development

Compatibility Studies in Pharmaceutical Materials and Packaging

A practical, risk-based guide to evaluating whether a pharmaceutical product and its packaging materials remain safe, stable, protective, and functional throughout processing, storage, distribution, and use.

Medicines interact with their surroundings from the moment they are filled into a bottle, vial, syringe, blister, tube, or bag. A package that looks suitable may still allow moisture or oxygen transfer, adsorb an ingredient, release a chemical into the product, lose seal integrity, or fail during storage and transport. Compatibility studies help development and quality teams identify these risks before a package is selected for routine manufacture.

Quick answer: What is a pharmaceutical packaging compatibility study?

A compatibility study evaluates whether a drug product and its container-closure or delivery system can remain in contact under intended manufacturing, storage, distribution, and use conditions without an unacceptable effect on product quality, patient safety, package protection, or delivery performance. The study plan is product-specific and combines scientific risk assessment with appropriate testing; there is no single universal test panel for every medicine and package.

This guide explains how to plan the assessment, distinguish compatibility work from extractables and leachables studies, select meaningful tests, set acceptance criteria, and document a defensible decision. It is intended for pharmaceutical development, analytical, packaging, quality assurance, regulatory, and manufacturing teams.

What Does Compatibility Mean for Pharmaceutical Packaging?

Packaging compatibility is the suitability of the complete packaging system for a particular product and intended use. It is broader than checking whether a container is made from an approved or familiar material. The product, the contact materials, the closure, the manufacturing process, and the labeled storage and use conditions must be considered together.

A container-closure system can include the bottle or vial, stopper, cap, liner, seal, coating, and other components that contain or protect the medicine. Components that do not directly touch the product may also matter when they can affect it—for example, an adhesive, ink, label, overwrap, or protective pouch that contributes to chemical migration, light protection, or package performance.

Compatibility is demonstrated when the proposed system maintains the product’s required quality and the package continues to perform its intended functions. These functions may include protection from light, moisture, oxygen, contamination, leakage, or physical damage; maintaining sterility where required; and enabling the correct dose to be withdrawn or administered.

Compatibility Studies vs. Extractables and Leachables

Extractables and leachables (E&L) are important parts of packaging assessment, but they are not synonyms for the full compatibility program.

Term	What it means	How it is used
Compatibility study	Overall evaluation of product-package interactions and package suitability, including quality, safety, protection, and functionality.	Connects material selection and packaging performance to the specific product, route, storage conditions, and use.
Extractables	Chemical substances that can be drawn from a packaging or delivery material under defined laboratory extraction conditions.	Helps characterize what could migrate from components and informs the design of product-specific leachables work.
Leachables	Chemical substances that migrate into the drug product or onto a product-contact surface under actual or simulated conditions of use.	Supports assessment of the patient’s potential exposure and whether the detected substances affect safety or product quality.
Container-closure integrity	Evidence that the assembled package maintains its required barrier or sterile boundary.	Confirms that leakage or ingress is controlled for the package’s intended function over its lifecycle.

USP General Chapters <1663> and <1664> provide frameworks for extractables and leachables assessments. They do not set one mandatory extraction condition, analytical procedure, or acceptance limit for every packaging-product combination. A scientifically justified, product-specific strategy is therefore essential.

Why Are Compatibility Studies Important?

• Protect product quality: Contact with packaging may affect potency, impurity levels, pH, appearance, dissolution, preservative content, or other critical attributes.
• Assess chemical safety: Potential migrants can require identification, quantification, and toxicological evaluation based on the substance, patient exposure, route, and duration of use.
• Confirm package protection: A package must control relevant exposure to moisture, oxygen, light, contamination, and physical stress.
• Check performance through shelf life: A closure, seal, dosing mechanism, or delivery device must continue to work under the intended storage and handling conditions.
• Support development and regulatory decisions: The data help justify material choices, proposed commercial packaging, specifications, shelf-life studies, and lifecycle changes.

In the United States, 21 CFR includes requirements for drug product containers and closures. In particular, 21 CFR 211.94 addresses reactivity, additive or absorptive effects, protection against external factors, and written standards and test methods. These requirements should be read with the applicable regulations in each target market.

Factors That Determine the Study Strategy

The depth of testing depends on the product-package combination. A risk assessment should identify the plausible interactions and explain how the selected evidence will address them.

Risk factor	Questions to consider	Potential study impact
Dosage form and route	Is the product an oral solid, liquid, topical, inhaled, ophthalmic, injectable, or biologic? What is the likely patient exposure?	Routes with direct tissue exposure or stringent sterility needs may require more focused safety, microbial-barrier, and package-integrity evidence.
Formulation chemistry	Does the product contain water, oils, surfactants, organic cosolvents, alcohols, extreme pH, or other ingredients that could increase interaction potential?	May trigger additional screening for sorption, material change, extractables, or leachables.
Contact configuration	Which parts touch the product, for how long, and at what surface-area-to-volume ratio? Does the patient administer the product through a device?	Determines which components and contact conditions should be represented in the study.
Process exposure	Will components be washed, coated, sterilized, depyrogenated, irradiated, or exposed to heat or reactive gases?	May affect material chemistry, package dimensions, seal behavior, or the potential for migrants.
Storage and distribution	What temperature, humidity, light, shipping stress, freezing, or freeze-thaw conditions are expected?	Requires representative stability conditions and, where justified, stress or thermal-cycle evaluation of the assembled package.
Supplier and material history	Are the material grade, formulation, manufacturing site, additives, or component design fully characterized and controlled?	Uncertainty or a material change can increase the need for characterization and bridging data.

Higher-risk combinations often include products in direct contact with elastomers or polymers, aqueous or solvent-containing liquids, high-surface-area delivery systems, and products with a long contact period. This is a prioritization principle, not a rule that every product in a category requires identical testing.

How to Plan a Compatibility Study: Step-by-Step

1. Define the intended use. Record dosage form, route, dose, contact duration, shelf life, in-use period, storage and shipping conditions, and whether the package has a delivery function.
2. Describe the complete system. Identify each primary and relevant secondary component, its material of construction, supplier and grade, dimensions, color, coating, adhesive, and any processing or sterilization treatment.
3. Map potential interactions. Consider chemical migration, adsorption or absorption, moisture or gas transmission, light exposure, corrosion, particulates, seal loss, deformation, and interference with dose delivery.
4. Use prior knowledge carefully. Review supplier data, compendial information, material history, previous product experience, and applicable regulatory requirements. Confirm that the information applies to the same grade, formulation, process, and contact conditions.
5. Select a staged test plan. Start with the highest-value screening and material characterization. Add extractables, leachables, functional, microbial, or stability testing when the risk assessment identifies a question that needs experimental evidence.
6. Study representative configurations. Use the proposed commercial package or a scientifically justified representative. Document any differences in size, material, fill volume, surface-area-to-volume ratio, closure, sterilization, or supplier.
7. Set criteria before testing. Define sample numbers, controls, time points, methods, reporting limits, acceptance criteria, and how unexpected findings will be handled. Have the responsible quality unit approve the protocol.
8. Review the whole evidence package. Interpret analytical results with package performance, stability trends, toxicological assessment where needed, and intended-use requirements. Record the rationale for the final selection and any residual risk.

Controlled protocols, execution steps, and reporting expectations should be described in an approved SOP. Raw data, calculations, chromatograms, sample traceability, and review decisions should be attributable, legible, contemporaneous, original, accurate, complete, and retrievable in line with ALCOA+ data-integrity principles.

Common Tests Used in Packaging Compatibility Assessments

Choose methods to answer defined scientific questions. The following are examples; they are not a universal checklist or a substitute for the applicable official compendial chapter and validated method.

Assessment area	Examples of tests or methods	What the data can show
Product quality and stability	Assay or potency, related substances, pH, color, appearance, particulate matter, dissolution or release, preservative content, moisture, and other product-specific attributes.	Whether the formulation changes in contact with the proposed system during storage or use.
Extractables and leachables	Non-targeted screening and targeted quantification using suitable platforms such as GC-MS, LC-MS or LC-HRMS, and ICP-MS for elemental species.	Potential material-derived compounds, actual product leachables, and the need for identification or toxicological assessment.
Sorption and permeation	Product-specific concentration or mass-balance studies; moisture-vapor or oxygen-transmission assessment where relevant.	Loss of active, preservative, flavor, solvent, or water; or exposure to oxygen or moisture through the package.
Material characterization	Visual and dimensional checks; material identity; relevant compendial tests for plastic, glass, elastomer, metal, or coating.	Whether supplied components match their approved material description and intended-use controls.
Package protection and integrity	Container-closure integrity testing, seal strength, leak testing, light transmission, torque, or other function-specific tests.	Whether the assembled package continues to protect the product and perform as intended.
Microbiological suitability	Microbial barrier or container-closure integrity approaches for sterile products; preservative or in-use evaluations when relevant.	Whether the system supports required microbiological quality over storage and use.
Distribution and handling	Package-specific transport simulation, vibration, compression, drop, thermal cycling, or freeze-thaw evaluation as justified.	Whether handling and environmental stresses compromise the container, closure, seal, label, or dose-delivery function.

Method selection matters.

A screening method should be broad enough for the chemical classes of concern, but its reporting threshold, sensitivity, selectivity, recovery, and suitability must be understood. When a result is used for a safety or release decision, qualify or validate the method for that intended use and document the scientific basis.

How to Set Acceptance Criteria

Acceptance criteria should be set for the specific product and package before the study begins. There is no single universal limit for total extractables, every leachable, or all material changes that applies to every dosage form and route.

• Product specifications: Relevant quality attributes must remain within approved or justified limits through the proposed shelf life and in-use period.
• Package function: The system must continue to meet its protection, closure, delivery, and usability requirements.
• Patient exposure: Leachables should be assessed using the maximum daily exposure, route, duration, and appropriate toxicological information.
• Analytical performance: Detection and quantitation capability should be appropriate for the risk threshold and the intended interpretation.
• Study variability: Sampling plans, replicate strategy, batch selection, and statistical treatment should support a reliable decision.
• Regulatory and compendial scope: Apply current official requirements and justify alternatives. Draft guidance should not be treated as binding or final.

Do not copy a threshold from another product without checking its assumptions. Route, dose, duration, patient population, chemical identity, and local tissue exposure can change the appropriate safety evaluation.

Worked Example: Screening a Liquid Product in a New Bottle

Consider a hypothetical low-pH oral liquid being evaluated in two proposed bottle-and-closure combinations. The formulation contains a preservative and a flavor component, and the product is intended to be stored for a defined shelf life after opening.

1. The team maps every product-contact surface, including the bottle, closure liner, and any seal that may contact the liquid after opening.
2. A risk assessment considers pH, water content, flavor chemistry, preservative, contact time, light exposure, and the expected storage temperature.
3. Both package options are compared for material identity, appearance, closure fit, light protection, and relevant transmission or integrity characteristics.
4. Product-filled samples are stored in representative systems. Assay, degradants, pH, appearance, preservative content, and other critical attributes are tested at predefined points.
5. If the risk assessment or screening indicates likely migration, an extractables profile is developed and product-specific leachables testing is planned. Results above the relevant assessment threshold are identified, quantified, and evaluated for safety and quality impact.
6. The team reviews the complete dataset and selects a package only if product quality and package function are supported through storage and use. The conclusion and any monitoring controls are documented.

This example does not prescribe a test list or result for real products. It shows how the study connects formulation risks to evidence and a documented decision.

Special Considerations for Sterile and Device-Enabled Products

For sterile medicines, compatibility includes maintaining the sterile barrier and package function throughout the claimed shelf life. A compatibility result at initial release does not, by itself, prove that an assembled closure remains integral after storage, transport, sterilization, or repeated use. The package-integrity method and acceptance criteria should be justified for the actual system and product.

For prefilled syringes, pens, inhalers, pumps, infusion sets, and other delivery systems, consider dose accuracy, extractables from fluid-path components, material behavior after sterilization or aging, and how the container interacts with the device. Evaluate the assembled system where the device could change product contact or delivery performance.

Biologics and other sensitive products may require additional attention to adsorption, aggregation, particles, potency, and temperature cycling. The exact tests depend on the molecule, formulation, container surface, and route; use product knowledge rather than assuming a standard package is automatically suitable.

Regulatory and Compendial Framework

Requirements vary by jurisdiction and product type. For US finished pharmaceuticals, 21 CFR 211.94 requires containers and closures not to affect the drug adversely and to provide adequate protection; written specifications and test methods are also required. Review the current text of 21 CFR 211.94 and the internal overview of 21 CFR pharmaceutical regulations.

ICH Q1A(R2) describes stability testing and calls for stability studies on the drug product in the container-closure system proposed for marketing. Use the current applicable stability guideline and regional implementation requirements when setting the formal stability protocol.

FDA’s August 2026 Container Closure Systems guidance is a draft document marked “Not for implementation”; it contains nonbinding recommendations. Likewise, FDA lists its Q3E extractables and leachables document as draft, not for implementation. The ICH Q3E draft and its work plan describe ongoing development, so verify their status before using them as a final regulatory basis.

USP <1663> and <1664> discuss extractables and leachables assessment frameworks. USP <661.1> and <661.2> address plastic materials of construction and plastic packaging systems. Select the current official chapter and requirements that apply to the material and product; compendial chapters do not eliminate the need for a product-specific risk assessment.

Documentation, Change Control, and Lifecycle Monitoring

A strong report should allow another reviewer to understand why the package was selected and how the conclusion was reached. Include at least:

• Study objective, product description, route, intended use, and package configuration.
• Supplier, material grade, component drawings, contact surfaces, and relevant manufacturing or sterilization processes.
• Risk assessment, prior knowledge, assumptions, and rationale for selecting or omitting tests.
• Approved protocol, sample and batch details, storage conditions, time points, analytical methods, and predefined criteria.
• Raw data references, calculations, method performance, deviations, investigation records, and final review.
• Conclusion, residual risks, package specifications, supplier controls, and ongoing stability or performance monitoring.

Evaluate packaging changes through formal change control. A new supplier, resin grade, additive package, closure liner, colorant, adhesive, sterilization process, or component geometry may change the risk profile even when the material name appears unchanged. Use a documented bridging assessment to decide whether existing evidence remains applicable or new testing is needed. Investigate unexpected results and manage corrective actions through a suitable CAPA process when required.

Compatibility work should operate within the site’s cGMP quality system, with approved controls for materials, methods, suppliers, records, and changes.

Frequently Asked Questions

What is the main purpose of a pharmaceutical packaging compatibility study?

It demonstrates that the product and its packaging system remain suitable together under intended processing, storage, distribution, and use conditions, without an unacceptable effect on safety, product quality, protection, or delivery performance.

Are extractables and leachables studies required for every medicine?

No single E&L study design applies to every product. A documented risk assessment should consider route, formulation, contact materials, exposure, package history, and uncertainty. Additional testing is appropriate when the identified risk cannot be adequately addressed by existing evidence.

What is the difference between extractables and leachables?

Extractables are substances removed from packaging under defined laboratory extraction conditions. Leachables migrate from packaging into a drug product or onto a product-contact surface under actual or simulated conditions of use.

Which tests are commonly included in compatibility work?

Depending on the product, studies may include product stability testing, material characterization, extractables or leachables analysis, sorption or permeation assessment, package-integrity testing, and delivery-function testing. The risk assessment determines which tests are relevant.

How long should a compatibility study run?

The duration and time points depend on the question being answered. Formal stability or leachables work should cover the relevant proposed shelf life and, where applicable, in-use period using justified storage conditions and sampling points.

Are USP <1663> and USP <1664> acceptance-criteria chapters?

They provide general frameworks for extractables and leachables assessments; they do not set one universal analytical procedure or pass/fail limit for every product and packaging combination. Product-specific criteria must be scientifically justified.

Does compatibility testing replace stability testing?

No. Compatibility testing informs package suitability. Stability testing evaluates how product quality changes over time in the proposed packaging under defined conditions. The two programs should be coordinated.

When should a packaging compatibility assessment be repeated?

Reassess when a change could affect material composition, product contact, processing, protection, integrity, dose delivery, or patient exposure. The change-control assessment determines whether a rationale, bridging test, or new study is needed.

What is the regulatory status of ICH Q3E?

ICH Q3E was issued as a draft guideline for consultation, and FDA lists its related Q3E guidance as draft and not for implementation. Check the current ICH and regional authority status before treating it as a final requirement.

Practical compatibility-study checklist

• Define the product, route, package configuration, storage, shipping, and in-use conditions.
• Identify product-contact and potentially relevant non-contact materials.
• Assess formulation, material, process, patient-exposure, and package-performance risks.
• Choose only the tests needed to answer the identified risks; justify the rationale.
• Set methods, reporting thresholds, sampling, and acceptance criteria before execution.
• Review product quality, chemical safety, package integrity, and delivery function together.
• Document the conclusion and reassess changes through quality-system change control.

References and Further Reading

1. eCFR, 21 CFR 211.94: Drug product containers and closures.
2. ICH Q1A(R2): Stability Testing of New Drug Substances and Products.
3. FDA, Container Closure Systems for Human Drugs and Biological Products, draft guidance, August 2026.
4. FDA, Q3E Guideline for Extractables and Leachables, draft guidance.
5. ICH Q3E: Guideline for Extractables and Leachables, Step 2 draft.
6. ICH Q3E Expert Working Group Work Plan, February 2026.
7. USP General Chapter <1663>: Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems.
8. USP General Chapter <1664>: Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging/Delivery Systems.
9. USP General Chapter <661.1>: Plastic Materials of Construction and USP General Chapter <661.2>: Plastic Packaging Systems for Pharmaceutical Use.

This educational article summarizes general development and quality concepts. Apply the current official requirements, approved product commitments, and site procedures relevant to the product and market.